Company profile for Rigerna Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Rigerna, named after ?Rigel? and ?RNA,? is an siRNA biotech company focused on advancing RNAi therapeutics. Dedicated to improving global health, Rigerna is developing a proprietary pipeline, including a Phase II trial for IgA nephropathy ranked among the top globally. The company has also created novel extra-hepatic siRNA delivery platforms, such as a kidney-targeted approach validated in NHP. Backed by $30M in initial fundin...
Rigerna, named after ?Rigel? and ?RNA,? is an siRNA biotech company focused on advancing RNAi therapeutics. Dedicated to improving global health, Rigerna is developing a proprietary pipeline, including a Phase II trial for IgA nephropathy ranked among the top globally. The company has also created novel extra-hepatic siRNA delivery platforms, such as a kidney-targeted approach validated in NHP. Backed by $30M in initial funding, Rigerna is poised to be a game-changer in the RNAi space.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
B2-702, No. 218 Xinghujie Road, Suzhou Industrial Park, JiangsuA3-1002, No. 8 ...
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty